Back to top
more

Invivyd, Inc. (IVVD)

(Real Time Quote from BATS)

$0.78 USD

0.78
376,215

-0.02 (-2.24%)

Updated Aug 11, 2025 03:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alector (ALEC) delivered earnings and revenue surprises of +33.33% and +177.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Royalty Pharma (RPRX) delivered earnings and revenue surprises of +3.64% and +5.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of -250% and 66.11%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of 40% and 2.75%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Investors Undervaluing Invivyd, Inc. (IVVD) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

The Zacks Analyst Blog Highlights INVIVYD, 21Vianet, FuboTV, Noodles and Digital Turbine

by Zacks Equity Research

INVIVYD, 21Vianet, FuboTV, Noodles and Digital Turbine are included in this Analyst Blog.

Sweta Killa headshot

5 Stocks That More Than Doubled Halfway Through Q1

by Sweta Killa

We highlight five stocks from different sectors that more than doubled halfway through the first quarter.

Zacks Equity Research

Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of -54.55% and 68.84%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of -8.11% and 53.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

All You Need to Know About Invivyd, Inc. (IVVD) Rating Upgrade to Strong Buy

by Zacks Equity Research

Invivyd, Inc. (IVVD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Invivyd (IVVD) Surges on Positive Data From COVID-19 Study

by Zacks Equity Research

Invivyd (IVVD) reports positive initial data from the phase III CANOPY study on VYD222 for the prevention of symptomatic COVID-19. Stock shoots up on the news.

Zacks Equity Research

Invivyd (IVVD) Stock Rises 18% in 3 Months: Here's Why

by Zacks Equity Research

Invivyd's (IVVD) shares rallied almost 18% over the past three months, owing to promising developments in its monoclonal antibody candidate, VYD222, designed to prevent symptomatic COVID-19 infection.

Zacks Equity Research

Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Harrow Health's (HROW) first-quarter top line is likely to have been driven by its recent product launches.

Zacks Equity Research

Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.

Zacks Equity Research

Revvity (PKI) to Report Q1 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

Revvity's (PKI) first-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.

Zacks Equity Research

After Plunging -26.71% in 4 Weeks, Here's Why the Trend Might Reverse for Invivyd, Inc. (IVVD)

by Zacks Equity Research

Invivyd, Inc. (IVVD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

Invivyd, Inc. (IVVD) Upgraded to Buy: Here's Why

by Zacks Equity Research

Invivyd, Inc. (IVVD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.